Chemotherapy-related cognitive dysfunction: current animal studies and future directions

R. Seigers(The Netherlands Cancer Institute), Jörg Dietrich(Massachusetts General Hospital), Olaf van Tellingen(Dutch Cancer Society), Sanne B. Schagen(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)
Brain Imaging and Behavior
August 14, 2013
10.1007/s11682-013-9250-3
Cited by 145

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768